drug · small molecule
pirtobrutinib
Marketedupdated 6mo agoby Eli Lilly and Co🔗 ChEMBL
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 2Small molecule drug with a maximum clinical stage of Approval (across all indications), with 5 approved and 3 investigational indications.
targets
Tyrosine-protein kinase BTK
all catalysts(0)
nothing on the calendar yet
Trials studying pirtobrutinib
- phase2A Study of Pirtobrutinib in Participants With Immune Thrombocytopenia
- phase3A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
- phase3Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL)
- phase2Phase 2 Open Label Randomized Study of Pirtobrutinib and Brexucabtagene Autoleucel in R/R MCL
- phase2Safety and Efficacy Study of Epcoritamab in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter's Syndrome
- phase3A Phase 3 Study to Compare the Efficacy of ICP-248 in Combination With Orelabrutinib Versus Pirtobrutinib in Participants With Relapsed or Refractory Mantle Cell Lymphoma (r/r MCL).
- phase3ROCKET-CLL Global Phase 3 Study: Rocbrutinib vs Pirtobrutinib in cBTKi-Pretreated R/R CLL/SLL
- phase4A Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Patent cliff
source: FDA Orange Bookfirst barrier falls
Jan 27, 2028
~1.2 years out
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (14)
- Sep 14, 2041formulationUS 12109193
- Sep 14, 2041formulationUS 12109193
- Jul 29, 2039formulationUS 12268666
- Jul 29, 2039formulationUS 12268666
- Dec 16, 2036compositionUS 10342780
- Dec 16, 2036compositionUS 10342780
- Dec 16, 2036method-of-use (U-4362)US 10464905
- Dec 16, 2036method-of-use (U-4362)US 10464905
- Dec 16, 2036compositionUS 10695323
- Dec 16, 2036compositionUS 10695323
- Dec 16, 2036method-of-use (U-4362)US 10918622
- Dec 16, 2036method-of-use (U-4362)US 10918622
- Dec 16, 2036compositionUS 12220401
- Dec 16, 2036compositionUS 12220401
FDA exclusivities (8)
- Dec 1, 2030ODE-451Orphan Drug (7y)4.0y
- Dec 1, 2030ODE-451Orphan Drug (7y)4.0y
- Jan 27, 2030ODE-424Orphan Drug (7y)3.2y
- Jan 27, 2030ODE-424Orphan Drug (7y)3.2y
- Dec 2, 2028I-981Indication (3y)2.0y
- Dec 2, 2028I-981Indication (3y)2.0y
- Jan 27, 2028NCENew Chemical Entity (5y)1.2y
- Jan 27, 2028NCENew Chemical Entity (5y)1.2y
News(10)
- Nurix drops one BTK degrader as momentum builds behind Roche-partnered optionNurix’s BTK degrader zelebrudomide may have survived a clinical hold in recent years, but that hasn’t stopped the California biotech from dropping the cancer drug.fiercebiotech · 1mo ago
- STAT+: In Duchenne muscular dystrophy, a promising therapy is available to a fortunate fewExon-skipping drugs present a critical test for the FDA’s goal of encouraging treatments for rare disease.stat · 1mo ago
- STAT+: Caribou Biosciences, biotech co-founded by Jennifer Doudna, is shutting downCaribou Biosciences is shutting down after failing to raise the money necessary to fund a late-stage clinical trial of its off-the-shelf CAR-T therapy for lymphoma.stat · 1mo ago
- STAT+: AstraZeneca opens new Boston siteAstraZeneca opened a new R&D site in Kendall Square yesterday, celebrating a $1 billion investment in the unsettled center of U.S. biotechnology after a spate of Chinese dealmaking.stat · 1mo ago
- STAT+: Are stem cell treatments about to have their day?Stem cells might be the next peptides, and how Trump's $90 checks will play out after the election.stat · 1mo ago
- Opinion: Why the FDA should not approve an ineffective multicancer screening test“Telling more people they have cancer is not progress; progress is having fewer people die from cancer,” H. Gilbert Welch writes of Grail’s multicancer screening test.stat · 1mo ago
- STAT+: Judges skewer HHS arguments in hearing over Medicare Advantage audits lawsuitFederal judges pushed back against the government's arguments in a Medicare Advantage case.stat · 1mo ago
- STAT+: Nobel-winning optogenetics research has led to experimental treatments for blindness and Alzheimer’sOptogenetics is now the foundational way through which we are able to understand how the brain worksstat · 1mo ago
- STAT+: New Trump regulations would clean up health care pricing disclosuresThe Trump administration is continuing its effort to bring more transparency to the cost of health care.stat · 1mo ago
- STAT+: Prices, prices, pricesWhy is health insurance so expensive? Read the latest stort in STAT's "Out of Pocket, Out of Reach" series to find out.stat · 1mo ago
Data sources
last refreshed 4h ago
Found something off?
comments(0)
5-min edit window · permanent after that